Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: quetiapine Clear all
Completed Not applicable Interventional Results available

Quetiapine for the Reduction of Cocaine Use

NCT00631748
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions
quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

NCT00090311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Scottsdale, Arizona • Riverside, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Brain Imaging of Quetiapine Response in Anxious Depression

NCT00982345
View directory record Official record
Conditions
Major Depression
Interventions
quetiapine (Seroquel XR)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.

NCT00550147
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Oros Methylphenidate, quetiapine
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia

NCT00090324
View directory record Official record
Conditions
Schizophrenia
Interventions
quetiapine fumarate tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
13 Years to 17 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
23
States / cities
Dothan, Alabama • Cerritos, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 2Phase 3 Interventional

Quetiapine in Social Anxiety Disorder

NCT00215254
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
quetiapine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

NCT00161018
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

NCT01052103
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Placebo, Standard of Care
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

NCT02845453
View directory record Official record
Conditions
Substance Use Disorders, Bipolar Disorder, Mood Disorders
Interventions
Quetiapine, Placebo
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
15 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04513912
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
75
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 17, 2026, 4:05 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020
View directory record Official record
Conditions
Bipolar Disorder
Interventions
divalproex ER, quetiapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

NCT00893581
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Quetiapine & Placebo, Lithium and Placebo, Healthy Controls
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

NCT02612948
View directory record Official record
Conditions
Psychomotor Agitation
Interventions
Quetiapine
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

NCT00208143
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
Interventions
Quetiapine, Risperidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00107731
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • Chula Vista, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 17, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain

NCT02281162
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
Interventions
Blood Draw
Other
Lead sponsor
Creighton University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

NCT00083954
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

NCT00114686
View directory record Official record
Conditions
Bipolar I Disorder, Alcohol Dependence
Interventions
Quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 60 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Quetiapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
25
States / cities
Garden Grove, California • La Mesa, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 17, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Quetiapine in Melancholic Depression

NCT01200901
View directory record Official record
Conditions
Depression, Healthy
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 17, 2026, 4:05 AM EDT
Withdrawn Phase 4 Interventional

RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)

NCT05085808
View directory record Official record
Conditions
Delirium, Morality, Quality of Life, Psych, Treatment Side Effects
Interventions
Trazodone, Quetiapine, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 4:05 AM EDT